Ivonescimab demonstrates superior efficacy in lung cancer trials

A recent clinical trial published in the renowned British medical journal The Lancet revealed promising results for Ivonescimab, a PD-1/VEGF bispecific antibody developed independently by Akeso Biotech, in treating late-stage non-small cell lung cancer patients.

Between November 2022 and August 2023, researchers conducted a randomized, double-blind phase 3 clinical trial involving 879 patients from 55 hospitals in China. The results indicated that patients in the Ivonescimab group had a median progression-free survival (PFS) of 11.1 months, significantly longer than the 5.8 months seen in the current top-selling cancer drug, Keytruda.

Regardless of patient age, gender, ECOG score, and other factors, the Ivonescimab group consistently outperformed the Keytruda group. Ivonescimab is poised to become a first-line treatment option for PD-L1 positive late-stage non-small cell lung cancer.

Ivonescimab Injection. [Photo/WeChat account: gzhpfb]

This innovative drug, produced at the Sino-Singapore Guangzhou Knowledge City Biopharmaceutical Base, offers new hope to cancer patients worldwide. In its 13 years, Akeso Biotech has evolved into an innovative pharmaceutical company integrating research and development, production, and commercialization, with over 50 innovative drug candidates in its pipeline.

The success of Akeso Biotech would not have been possible without the support of Huangpu district, which has fostered a bio-pharmaceutical cluster comprising 4,800 companies, propelling the region to the forefront of China's bio-pharmaceutical industry development.

Share - WeChat